Skip to main content

Table 2 Additional proportion of variability of the three components that contributed to total pain burden at baseline

From: Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)

Additional proportion of variability that contributed to total pain burden at baselinea

Episodic migraineb

Chronic migrainec

Frequency of monthly migraine headache days

22.6%

13.2%

Duration (hours per migraine headache days)

57.4%

61.1%

Severity of remaining migraine headache days

4.9%

4.8%

  1. aSemi-partial provide the unique (or additional) proportion of variability explained by the particular variable in its ability to predict the outcome after accounting for the other 2 components
  2. bIncludes pooled data from two parallel 6-month studies
  3. cIncludes data from a 3-month study